Early-Bird registrations are available.
Set the table for your success in 2018! World Stem Cell Summit is the first major stem cell and regenerative medicine meeting in January. The single, multi-track meeting designed to deliver timely and comprehensive content along with the valuable connections you need to accomplish your goals.
WSCS will be co-located for the first time with the Phacilitate Leaders Forum, which incorporates the Cell & Gene Therapy World and Immuno-Oncology Frontiers World conferences. The scope of this combined event is historic in the way that it supports industry-academic convergence in a bid to accelerate innovation in the field. It will be the largest ecosystem and total partnering meeting in the regenerative space designed to build relationships and forge collaborations. The Summit and Phacilitate share a sophisticated on-site partnering platform that allows you to identify the attendees you want to meet from the co-located events. That enables you to ask for a meeting and have it automatically fit into your meeting schedule.
The first provisional schedule will be posted this week on our website.
Here are a few sample sessions:
6th Annual Japanese Symposium - Recent progress of industry-academic open innovation in Japan for cell application: Takashi Asada, PhD, Kyoto University (moderator); Prof. Norio Nakatsuji, Kyoto University; Hideyuki Okano, MD, PhD, Keio University & Japanese Society for Regenerative Medicine; Akihiko Iwai, PhD, Astellas Pharma & Forum for Innovative Regenerative Medicine (FIRM); Masato Ibuki, Kaneka Corporation; Masayo Yumato, PhD, Rohto Pharmaceutical
Using iPSC’s to understand and treat Parkinson’s: Dr. Jeanne Loring, Scripps and other members of GForce-PD
Global Cord Blood & Tissue Roundtable: Dr. Joanne Kurtzberg, Carolinas Cord Blood Bank at Duke; Dr. Yijia Lee, Yunnan Province Stem Cell Bank; Dr. Wofgang Knirsch, Vita 34 AG; Jakub Baran, Famicord Group (Poland); Elizabeth Shpall, MD., University of Texas MD Anderson Center
Why clinical trials fail: Dan Gincel, PhD., Maryland Stem Cell Research Fund
Case study: Developing a cell therapy combination product for diabetes Mark Zimmerman, Viacyte